Adaptimmune and TCR2 have filed a joint proxy statement with the SEC in connection with their merger agreement, and two complaints have been filed by TCR2 stockholders alleging misrepresentation in the proxy statement.
AI Assistant
ADAPTIMMUNE THERAPEUTICS PLC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.